Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Launches Depend Mostly On Patents After Supreme Court Ruling

Executive Summary

US high court says biosimilar sponsors do not have to wait until after FDA approval to start countdown clock for marketing, but patent litigation may impede launches.

Advertisement

Related Content

Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
EU’s CHMP Expected To OK Another Biosimilar Humira
Boehringer Ingelheim Limbering Up With Humira Biosimilar
Biosimilar Litigation: Janssen Vs. Samsung Anticipates Supreme Court Decision
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098934

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel